Notice: This company has been marked as potentially delisted and may not be actively trading. First Wave BioPharma (FWBI) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesTrends Get the Latest News and Ratings for FWBI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for First Wave BioPharma and its competitors. Enter your email to sign up for newsletter Sign Up FWBI Analyst Ratings Over TimeTypeCurrent Forecast11/13/23 to 11/12/241 Month Ago10/14/23 to 10/13/243 Months Ago8/15/23 to 8/14/241 Year Ago11/13/22 to 11/13/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$36.00$36.00$36.00$200.00Forecasted UpsideN/A1,116.22% Upside1,116.22% Upside3,497.12% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover FWBI Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History FWBI Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table First Wave BioPharma Stock vs. The CompetitionTypeFirst Wave BioPharmaMedical CompaniesS&P 500Consensus Rating Score 2.50 2.80 2.50Consensus RatingModerate BuyModerate BuyHoldPredicted UpsideN/A25,508.18% Upside7.92% UpsideNews Sentiment RatingNeutral NewsSee Recent FWBI NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/25/2024HC Wainwright2 of 5 starsY. ChenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/15/2024Roth Mkm1 of 5 stars Lower TargetBuy ➝ Buy$40.00 ➝ $36.00+661.10%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:59 PM ET. FWBI Forecast - Frequently Asked Questions What is First Wave BioPharma's forecast for 2025? According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for First Wave BioPharma is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. Should I buy or sell First Wave BioPharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last twelve months. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FWBI shares. Does First Wave BioPharma's stock price have much upside? According to analysts, First Wave BioPharma's stock has a predicted upside of ∞ based on their 12-month stock forecasts. Do Wall Street analysts like First Wave BioPharma more than its competitors? Analysts like First Wave BioPharma less than other "medical" companies. The consensus rating score for First Wave BioPharma is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how FWBI compares to other companies. Stock Forecasts and Research Tools Related Companies VIRX Stock Forecast ENLV Stock Forecast BCTX Stock Forecast MIRA Stock Forecast ITRM Stock Forecast BTAI Stock Forecast LSTA Stock Forecast BIVI Stock Forecast BOLT Stock Forecast GDTC Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. This page (NASDAQ:FWBI) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWall Street’s “Secret” Land Grab33-year Wall Street veteran Dylan Jovine says there is one stock that could soar as high as 1,000% or more wit...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Wave BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share First Wave BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
